Skip to main content

Table 1 Cox univariate and multivariate analysis of RFS, BCSS and OS in cohort 1 (RPPA), and also stratified into the ER-positive cohort

From: Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer

 

RFS

 

BCSS

 

OS

 
 

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

All patients (n = 712)

      

PRDX1 protein

Univariate

 

Univariate

 

Univariate

 

  Low

1

 

1

 

1

 

  High#

0.67 (0.52 - 0.88)

0.004

0.65 (0.48 - 0.88)

0.005

0.76 (0.59 - 0.98)

0.036

PRDX1 protein

Multivariate*

 

Multivariate*

 

Multivariate*

 

  Low

1

 

1

 

1

 

  High#

0.94 (0.65 - 1.35)

0.720

0.84 (0.55 - 1.28)

0.405

0.93 (0.66 - 1.31)

0.668

ER + patients (n = 429)

      

PRDX1 protein

Univariate

 

Univariate

 

Univariate

 

  Low

1

 

1

 

1

 

  High#

0.62 (0.43 - 0.90)

0.011

0.59 (0.39 – 0.90)

0.014

0.79 (0.57 - 1.11)

0.171

PRDX1 protein

Multivariate*

 

Multivariate*

 

Multivariate*

 

  Low

1

 

1

 

1

 

  High#

0.65 (0.37 - 1.13)

0.129

0.56 (0.31 - 1.01)

0.055

0.78 (0.50 - 1.23)

0.295

  1. *Multivariate analysis included adjustment for tumor size, grade, age, nodal, ER, PR and Her2 status. Tumor size and age are both continuous variables. PRDX1 protein expression levels are stratified by the median. #PRDX1 protein expression levels are stratified by the median protein expression value. BCSS, breast cancer-specific survival; CI, confidence interval; ER, estrogen receptor; Her2, human epidermal growth factor receptor 2; HR, hazard ratio; OS, overall survival; PR, progesterone receptor; PRDX1, peroxiredoxin 1; RFS, recurrence-free survival; RPPA, reverse phase protein arrays.